Many patients who present with Pseudomonas aeruginosa bacteremia have been previously exposed to antibiotics. To assess whether resistance of bacteremic strains to antipseudomonal antibiotics (piperacillin, ceftazidime, imipenem, ciprofloxacin, or aminoglycosides) is associated with previous exposure to these drugs, a case-control study including 267 cases of P. aeruginosa bacteremia was conducted. Twenty-five percent of the episodes had been preceded by the exposure to an antipseudomonal antibiotic. Eighty-one strains were resistant to at least 1 antibiotic; 186 were susceptible to all drugs. Via univariate analysis, the risks of resistance to ceftazidime and imipenem were found to be significantly associated with previous receipt of these agents. Using multivariate analysis, exposure to any antipseudomonal antibiotic as a monotherapy was found to be associated with an increased risk of subsequent resistance to itself (odds ratio, 2.5;
rium acquires new resistances during antibiotic therapy [6] . As a result of this capacity to rapidly acquire resistance mechanisms, P. aeruginosa bacteremia frequently follows other infections treatment with antibiotic regimen that include antipseudomonal drugs.
Because the symptoms of P. aeruginosa bacteremia are nonspecific, the initial antibiotic therapy for possible P. aeruginosa bacteremia is almost always empirical, with a pending identification of the responsible pathogen and an unknown antibiotic resistance profile. Inappropriate antibiotic treatment of bacteremia is associated with a significantly poorer outcome [7] . It is therefore important to determine whether recent exposure to antibiotics with antipseudomonal activity increases the risk of resistance of bacteremic strains to these agents [3] . Answering this question would help clinicians choose the most adequate empirical treatment in clinical situations that include P. aeruginosa bacteremia as a possible cause.
We identified 267 P. aeruginosa bacteremic events that occurred at a tertiary-care hospital and conducted a case-control study to determine whether recent exposure to antibiotics with antipseudomonal activity was associated with an increased risk of resistance toward these drugs.
PATIENTS AND METHODS
This study took place at the Geneva University Hospital, Switzerland, a 1000-bed tertiary-care teaching center that serves as a first-line medical center for an urban population of ∼400,000 inhabitants and as a referral center for a larger population coming from both Switzerland and nearby France.
Study design. We used the microbiology laboratory database of the hospital to identify all inpatients that had had 1 or several blood cultures positive for P. aeruginosa from 1 January 1989 through 31 December 1998. Medical records were reviewed for information on demographic characteristics, clinical presentation of bacteremia, primary site of P. aeruginosa infection, underlying medical conditions, immunosuppression at the time of bacteremia, invasive procedures, laboratory results of antibiotic susceptibility, and recent antibiotic treatment including an agent with antipseudomonal activity. An "episode" of P. aeruginosa bacteremia was defined as a positive blood culture with this pathogen. "Previous monotherapy" was defined as a therapy that started within 30 days before the positive blood culture, included only 1 of the antipseudomonal antibiotics used in our institution (piperacillin, ceftazidime, imipenem, ciprofloxacin, gentamicin, and amikacin), was administered for 148 h, and was stopped !15 days before the bacteremia. "Previous combination therapy" was defined as follows: treatment was initiated within 30 days and stopped !15 days before the positive blood culture; it included the concomitant use for у48 h of a b-lactam antibiotic, and either an aminoglycoside or ciprofloxacin, or the combination ciprofloxacin plus aminoglycoside, with an exposure to a single drug for no more than 48 h. All other patterns of antibiotic exposure were classed in the "no previous treatment" group. In a first analysis, "cases" were defined as episodes of bacteremia caused by a strain of P. aeruginosa resistant to at least 1 antipseudomonal antibiotic and "controls" as episodes involving strains susceptible to all 6 antibiotics. Three categories of exposure were examined: any previous combination therapy, any previous monotherapy, and no previous therapy. In subsequent analyses, cases were episodes caused by a strain resistant to 1 specified antibiotic, and controls were episodes caused by a strain susceptible to that same antibiotic; hence, bacteremic strains resistant to у2 antibiotics contributed more than once to these analyses. Patients were considered exposed if they had received the specified antibiotic either as a monotherapy or as an agent included in a combination therapy.
Microbiology. A minimum of 2 pairs of blood cultures was performed at the time of presumed bacteremia. P. aeruginosa was identified at the laboratory of clinical microbiology via standard clinical microbiology methods [8] . Antimicrobial susceptibility was determined by disk diffusion methods according to the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) [9] . An isolate was considered susceptible, intermediate, or resistant according to the criteria of the NCCLS. The isolates with intermediate susceptibility were classified as resistant for analysis. No molecular typing was performed.
Statistical analysis. We calculated crude ORs and exact 95% CI to evaluate the potential relation between previous antipseudomonal therapy and resistance of the bacteremic strain. Two-tailed Fisher's exact tests were used for the comparison of proportions.
Multiple logistic regression was used to assess whether having received a previous monotherapy or combination therapy including a specific antipseudomonal agent were independent risk factors for resistance of the bacteremic isolate to that same agent. Because data were scarce, observations corresponding to all 6 antibiotics were pooled in a stratified model. Therefore, each episode of bacteremia contributed 5 times to the model (1 stratum per antibiotic); variance estimates were adjusted to reflect the resulting dependence among observations. Previous monotherapy and combination therapy were forced in the model; we further considered independent variables with P ! in univariate logistic regression (data not shown). To limit .2 the risk of overfitting, no interaction terms were tested. Regression analyses were performed by STATA version 6.0 (STATA Corporation).
RESULTS

Characteristics of bacteremic episodes.
During the study period, 273 P. aeruginosa bacteremic episodes occurred in 267 patients. Computerized microbiological data and medical records were available for all patients. Four patients had 2 independent episodes of bloodstream infections separated by 14-69 days, and 1 person had 3 episodes over a period of 50 days. We report here on the 267 initial episodes of P. aeruginosa bacteremia.
The overall incidence of P. aeruginosa bacteremia at the Geneva University Hospital was 1 per 1000 admissions (range per year, 0.63‰-1.45‰). P. aeruginosa bacteremia accounted for 5.4% (range, 3.7%-7.6%) of all bloodstream infections. The mean age of the patients was 59 years (range, 1 day to 93 years; SD, 22 years), and approximately two-thirds were men (table  1) . At the time of bacteremia, 32% of patients were hospitalized in acute-care and 14% in chronic-care medical services, 17% were in surgical wards, and 37% were in intensive care units (medical and surgical). The most common sites of primary infection were the respiratory and the urinary tracts; no source Sixty-six patients (24.7%) had been exposed to an antibiotic therapy active against P. aeruginosa (monotherapy, ; n p 54 combination therapy, ; monotherapy followed by a comn p 8 bination therapy with 2 other agents, ; table 1) before n p 2 the bacteremic event. Of these regimens, 36 included imipenem; 9, piperacillin; 9, ciprofloxacin; 8, ceftazidime; and 32, an aminoglycoside (table 2). Of the 267 P. aeruginosa blood isolates, 15 were not tested for susceptibility to imipenem and 1 isolate was not tested for susceptibility to piperacillin. A total of 186 blood isolates (70%) were susceptible to all tested antibiotics, 35 (13%) were resistant to 1 antibiotic, 27 (10%) to 2 antibiotics, and 19 (7%) to у3 antibiotics. Forty-three isolates (16%) were resistant to an aminoglycoside (gentamicin or amikacin), 41 (15%) to imipenem, 29 (11%) to piperacillin, 16 (6%) to ceftazidime, and 15 (6%) to ciprofloxacin.
Univariate risk factors for resistance to у1 antipseudomonal agent. Patients who had been exposed to previous therapy including an antipseudomonal agent were marginally more likely to have experienced a P. aeruginosa bloodstream infection with a strain resistant to у1 of the study antibiotics than patient who had not been previously exposed (OR, 1.8; 95% CI, 1.0-3.4;
; table 1). Previous exposure to a P p .06 monotherapy was marginally associated with an increased risk of resistance (OR, 1.8; 95% CI, 0.92-3.6;
). No statis-P p .07 tically significant association was found between a previous combination therapy and risk of resistance (OR, 1.8; 95% CI, 0.35-7.8;
). Bacteremia experienced between 1993 and P p .47 1998, hospitalization on other units than the acute-care medical services, urinary source of infection, septic shock as clinical mode of presentation ( ), and having experienced an P p .06 invasive procedure (except a drainage tube) were other factors significantly associated with resistance to у1 antibiotic.
Crude risk of resistance to an antibiotic after exposure to that same antibiotic. In univariate analysis, we did not attempt to distinguish between situations where an antibiotic had been received as a monotherapy or as part of a combination therapy (too few patients had received any specific antibiotic as part of a combination therapy). Previous exposure to ceftazidime was significantly associated with an increased risk of resistance of the bacteremic isolate toward this antibiotic (OR, 11.4; 95% CI, 1.6-64.7;
; table 2). Similarly, previous P p .008 treatment with imipenem was significantly associated with an increased risk of resistance toward itself (OR, 2.7; 95% CI, 1.1-6.5;
), and previous exposure to piperacillin was P p .02 marginally associated with an increased risk of resistance (OR, 4.4; 95% CI, 0.67-22.1;
). In contrast, previous expo-P p .06 sure to ciprofloxacin or an aminoglycoside was not associated with an increased risk of resistance to themselves.
Average adjusted risk of resistance to an antibiotic after exposure to that same antibiotic. In multivariate analysis stratified for antipseudomonal agents, previous monotherapy with an antipseudomonal antibiotic was independently associated with an increased risk of subsequent resistance of the bacteremic strain to that antibiotic (OR, 2.5; 95% CI, 1.3-4.8;
; table 3). The risk of subsequent resistance was not P p .006 significantly increased among patients who had received a combination therapy (OR, 1.8; 95% CI, 0.55-5.6;
). How-P p .34 ever, no significant difference was observed between combination therapies and monotherapies in terms of independent risk of subsequent resistance (OR, 0.70; 95% CI, 0.20-2.53;
). Finally, severe sepsis or shock as the primary man-P p .59 ifestation of bacteremia was marginally associated with an increased risk of resistance after controlling for previous antibiotic therapy. Severe sepsis or septic shock 1.6 (0.94-2.6) .08
NOTE. Stratified logistic regression analysis in which each episode of bacteremia contributed 5 times to the model (i.e., once per antipseudomonal agent). Variance estimates were adjusted for the resulting dependence among observations.
DISCUSSION
For clinicians who initiate empiric treatment in a clinical situation compatible with P. aeruginosa bacteremia, it is crucial to assess the potential risk of a resistant causative bacterium. In this retrospective study, 80 (30%) of 267 consecutive bacteremic isolates of P. aeruginosa were resistant to у1 antipseudomonal drug. Twenty-four percent of bacteremic episodes occurred in patients who had been previously exposed to one or several of these agents. Imipenem and aminoglycosides were the most commonly administered antibiotics before the bacteremic event, and they were also the agents toward which the bacteremic isolates were the most frequently resistant. In univariate analysis, previous exposure to ceftazidime, piperacillin, and imipenem were significantly or marginally associated with an increased risk of resistance of the bacteremic isolate to themselves. After controlling for covariates, the average resistance of the bacteremic strain to an antibiotic was 2.5 times more likely when the patient had received previous monotherapy with this antibiotic that when he had not been exposed to it. No other treatment variable and none of the characteristics related to patients and hospital environment independently predicted resistance of the bacteremic isolate to an antipseudomonal drug.
Exposure to antibiotics predisposes patients to colonization with P. aeruginosa intrinsically resistant to these agents. P. aeruginosa has also the capacity to rapidly become resistant during the course of an antipseudomonal drug treatment [10] . Therefore, previous therapies increase the risk of infections with selected resistant P. aeruginosa isolates [7] . Moreover, through the selection of resistant strains, previous exposure to antibiotics also increases the risk for the subsequent administration of an inadequate antimicrobial treatment [11] . Finally, inadequate antibiotic treatments of P. aeruginosa bloodstream infections significantly increase the case-fatality rate [7, [11] [12] [13] , prolong the hospital stay, and generate higher general costs [3, 14] .
In this study, aminoglycosides were frequently administered before the bacteremic event, and resistance toward these agents was common among the bacteremic isolates. Nevertheless, previous exposure to aminoglycosides was not associated with an increased risk of resistance. A possible explanation for this finding is that resistance toward aminoglycosides in these patients might not be due to a mechanism involving exposure to this antimicrobial class, but rather to the induction of the MexXYOprM efflux system [15] by the exposure to other drugs. This multidrug efflux system of P. aeruginosa is responsible for resistance to aminoglycosides and is not only induced by exposure to aminoglycosides, but also by exposure to other classes of antibiotics such as macrolides or tetracycline [16] . The antibiotic ranking for postexposure risk of resistance differed in this study and that of Carmeli et al. [10] . In the latter work, exposure to imipenem was associated with the highest risk of resistance and ceftazidime with the lowest-findings the opposite of ours. Different study populations could explain these differences. Indeed, the study of Carmeli et al. [10] focused not only on bacteremic strains, but on both colonizing and invasive isolates from various clinical sites. In addition, patients included in the study by Carmeli et al. [10] were initially colonized with organisms susceptible to the antibiotics to which subsequent resistance was detected, and a minority of these resistant strains were proven to have emerged from the original susceptible clone. However, the study by Carmeli et al. [10] relied upon an even smaller number of resistant isolates than ours (28 vs. 81). One limitation of our work is the absence of genotyping of susceptible colonizing and resistant bacteremic strains, making it impossible to distinguish new acquisition of resistance by a previously susceptible strain from superinfection with a genetically unrelated resistant strain.
Considerable debate exists concerning the usefulness of combination therapies (usually the addition of an aminoglycosides to a b-lactam antibiotic) in order to reduce the risk of emergence of resistance in P. aeruginosa isolates [17] [18] [19] [20] . In contrast to previous monotherapies, previous combination therapies did not predict subsequent resistance in this study. However neither us nor Carmeli et al. [10] found a significant difference in risk of resistance when monotherapy and combination therapies were directly compared with each other. We studied one of the largest retrospective series of P. aeruginosa bacteremia and had almost no missing information. Nevertheless, our study lacked power to identify differences in risk of resistance across antibiotics, as well as between monotherapy and combination therapies.
In conclusion, bacteremic events that followed exposure to antipseudomonal antibiotics were more likely to be due to resistant P. aeruginosa strains. Therefore, when initiating an empiric treatment for a possible P. aeruginosa bacteremia, clinicians should avoid previously administered antibiotics, and in particular, they should avoid those that had been administered as monotherapies.
